Shares of Biocon Ltd rose as a lot as 2% on Wednesday, 21 Could, after its subsidiary said that its Japanese industrial associate has launched the Ustekinumab BS Subcutaneous injection for the therapy of psoriasis vulgaris and psoriatic arthritis.
Ustekinumab BS Subcutaneous injection is a biosimilar model of the reference medication Stelara (Ustekinumab). Biocon Biologics developed and manufactured it, whereas Yoshindo Inc. commercialised and offered it in Japan, in response to the corporate’s trade submitting.
Following regulatory approval, the enterprise entered right into a settlement and license settlement with Janssen Biotech Inc., Janssen Sciences Eire, and Johnson & Johnson, collectively often called Janssen, in April 2024 to commercialise Ustekinumab in Japan.
Biocon Biologics’ biosimilar was accepted by Japan’s Prescription drugs and Medical Gadgets Company in December 2024. Biocon Biologics beforehand launched Ustekinumab in the US and Europe in February of this 12 months.
Biocon’s March quarter outcomes exceeded expectations, with the generics unit main the way in which. The introduction of the Revlimid generic in the US was a significant driver of development. Throughout the March quarter, necessary development drivers included a UK-Netherlands retail tie-up for Liraglutide, in addition to the launch of most cancers and blood stress therapy capsules within the US.
Biocon’s 4 biosimilars exceeded $200 million in gross sales apiece through the fiscal 12 months 2025.
At 12:27 pm, the shares of Biocon had been buying and selling 1.80% greater at Rs 338.50 on NSE.
Questioning About Biocon Ltd? The Analyst Has Solutions.
Uncover the following massive funding! Unicorn Indicators’ IPO screener helps you determine promising preliminary public choices. Obtain Unicorn Indicators and get forward of the curve! Signal Up Now & Discover Your Subsequent IPO Gem!
